Breast Cancer Distant Recurrence Lead Time Interval by Detection Method in an Institutional Cohort

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2020 Nov 21

PMID 33218313

Citations 2

Authors

Henry G Kaplan

Judith A Malmgren

Mary K Atwood

Affiliations

Soon will be listed here.

Abstract

Background: Lead time, the interval between screen detection and when a disease would have become clinically evident, has been cited to explain longer survival times in mammography detected breast cancer cases (BC).

Methods: An institutional retrospective cohort study of BC outcomes related to detection method (mammography (MamD) vs. patient (PtD)). Cases were first primary invasive stage I-III BC, age 40-74 years (n = 6603), 1999-2016. Survival time was divided into 1) distant disease-free interval (DDFI) and 2) distant disease-specific survival (DDSS) as two separate time interval outcomes. We measured statistical association between detection method and diagnostic, treatment and outcome variables using bivariate comparisons, Cox proportional hazards analyses and mean comparisons. Outcomes were distant recurrence (n = 422), DDFI and DDSS.

Results: 39% of cases were PtD (n = 2566) and 61% were MamD (n = 4037). MamD cases had a higher percentage of Stage I tumors [MamD 69% stage I vs. PtD 31%, p < .001]. Rate of distant recurrence was 11% among PtD BC cases (n = 289) vs. 3% of MamD (n = 133) (p < .001). Order of factor entry into the distant recurrence time interval (DDFI) model was 1) TNM stage (p < .001), 2) HR/HER2 status (p < .001), 3) histologic grade (p = .005) and 4) detection method (p < .001). Unadjusted PtD DDFI mean time was 4.34 years and MamD 5.52 years (p < .001), however when stratified by stage, the most significant factor relative to distant recurrence, there was no significant difference between PtD and MamD BC. Distant disease specific survival time did not differ by detection method.

Conclusion: We observed breast cancer distant disease-free interval to be primarily associated with stage at diagnosis and tumor characteristics with less contribution of detection method to the full model. Patient and mammography detected breast cancer mean lead time to distant recurrence differed significantly by detection method for all stages but not significantly within stage with no difference in time from distant recurrence to death. Lead time difference related to detection method appears to be present but may be less influential than other factors in distant disease-free and disease specific survival.

Citing Articles

Noninvasive Risk Prediction Models for Heart Failure Using Proportional Jaccard Indices and Comorbidity Patterns.

Tang Y, Wang C, Mitra P, Pai T Rev Cardiovasc Med. 2024; 25(5):179.

PMID: 39076472 PMC: 11267177. DOI: 10.31083/j.rcm2505179.

Is Immediate Lymphatic Reconstruction on Breast Cancer Patients Oncologically Safe? A Preliminary Study.

Lin Y, Kuan C, Lo C, Tsai L, Wu C, Huang C Plast Reconstr Surg Glob Open. 2023; 11(11):e5385.

PMID: 37941816 PMC: 10629743. DOI: 10.1097/GOX.0000000000005385.

References

Hofvind S, Vacek P, Skelly J, Weaver D, Geller B . Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst. 2008; 100(15):1082-91. PMC: 2720695. DOI: 10.1093/jnci/djn224. View

Jatoi I, Anderson W . Breast-Cancer Tumor Size and Screening Effectiveness. N Engl J Med. 2017; 376(1):93. DOI: 10.1056/NEJMc1614282. View

Kaplan H, Malmgren J . The breast cancer overdiagnosis conundrum: an oncologist's viewpoint. Ann Intern Med. 2013; 158(1):60-1. DOI: 10.7326/0003-4819-158-1-201301010-00011. View

Tabar L, Dean P, Chen T, Yen A, Chen S, Fann J . The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer. 2018; 125(4):515-523. PMC: 6588008. DOI: 10.1002/cncr.31840. View

Massat N, Sasieni P, Tataru D, Parmar D, Cuzick J, Duffy S . Explaining the Better Prognosis of Screening-Exposed Breast Cancers: Influence of Tumor Characteristics and Treatment. Cancer Epidemiol Biomarkers Prev. 2015; 25(3):479-87. DOI: 10.1158/1055-9965.EPI-15-0804. View

Schunemann H, Lerda D, Quinn C, Follmann M, Alonso-Coello P, Rossi P . Breast Cancer Screening and Diagnosis: A Synopsis of the European Breast Guidelines. Ann Intern Med. 2019; 172(1):46-56. DOI: 10.7326/M19-2125. View

Lannin D, Wang S . Are Small Breast Cancers Good because They Are Small or Small because They Are Good?. N Engl J Med. 2017; 376(23):2286-91. DOI: 10.1056/NEJMsr1613680. View

Smith-Bindman R, Chu P, Miglioretti D, Sickles E, Blanks R, Ballard-Barbash R . Comparison of screening mammography in the United States and the United kingdom. JAMA. 2003; 290(16):2129-37. DOI: 10.1001/jama.290.16.2129. View

HUTCHISON G, Shapiro S . Lead time gained by diagnostic screening for breast cancer. J Natl Cancer Inst. 1968; 41(3):665-81. View

10.

Myers E, Moorman P, Gierisch J, Havrilesky L, Grimm L, Ghate S . Benefits and Harms of Breast Cancer Screening: A Systematic Review. JAMA. 2015; 314(15):1615-34. DOI: 10.1001/jama.2015.13183. View

11.

Tabar L, Vitak B, Chen T, Yen A, Cohen A, Tot T . Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011; 260(3):658-63. DOI: 10.1148/radiol.11110469. View

12.

Kaplan H, Malmgren J, Atwood M, Calip G . Effect of treatment and mammography detection on breast cancer survival over time: 1990-2007. Cancer. 2015; 121(15):2553-61. PMC: 5705063. DOI: 10.1002/cncr.29371. View

13.

Wells C, Feinstein A . "Benign" tumors and "early detection" in mammography-screened patients of a natural cohort with breast cancer. Arch Intern Med. 2000; 160(8):1109-15. DOI: 10.1001/archinte.160.8.1109. View

14.

Mook S, J van t Veer L, Rutgers E, Ravdin P, van de Velde A, van Leeuwen F . Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst. 2011; 103(7):585-97. DOI: 10.1093/jnci/djr043. View

15.

Arleo E, Monticciolo D, Monsees B, McGinty G, Sickles E . Persistent Untreated Screening-Detected Breast Cancer: An Argument Against Delaying Screening or Increasing the Interval Between Screenings. J Am Coll Radiol. 2017; 14(7):863-867. DOI: 10.1016/j.jacr.2017.01.038. View

16.

Malmgren J, Calip G, Atwood M, Mayer M, Kaplan H . Metastatic breast cancer survival improvement restricted by regional disparity: Surveillance, Epidemiology, and End Results and institutional analysis: 1990 to 2011. Cancer. 2019; 126(2):390-399. PMC: 7004046. DOI: 10.1002/cncr.32531. View

17.

Shapiro S, Goldberg J, HUTCHISON G . Lead time in breast cancer detection and implications for periodicity of screening. Am J Epidemiol. 1974; 100(5):357-66. DOI: 10.1093/oxfordjournals.aje.a112046. View

18.

Welch H, Prorok P, OMalley A, Kramer B . Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med. 2016; 375(15):1438-1447. DOI: 10.1056/NEJMoa1600249. View

19.

Taplin S, Ichikawa L, Buist D, Seger D, White E . Evaluating organized breast cancer screening implementation: the prevention of late-stage disease?. Cancer Epidemiol Biomarkers Prev. 2004; 13(2):225-34. DOI: 10.1158/1055-9965.epi-03-0206. View

20.

Siu A . Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016; 164(4):279-96. DOI: 10.7326/M15-2886. View